Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
Damien Cohen(Université Claude Bernard Lyon 1), Isabelle Chemin(Inserm), Pierre Garcia(Université Claude Bernard Lyon 1), Maud Lemoine(St Mary's Hospital), Yusuke Shimakawa(Institut Pasteur), Mark Thursz(St Mary's Hospital), Umberto D’Alessandro(MRC Unit the Gambia), Catherine Voegele(Centre international de recherche sur le cancer), Clément Guillot(Université Claude Bernard Lyon 1), Fabien Zoulim(Université Claude Bernard Lyon 1), Sophie Alain(Université de Limoges), Geoffroy Durand(Centre international de recherche sur le cancer), Nora Kakwata-Nkor Deluce(Université Claude Bernard Lyon 1), Gibril Ndow(MRC Unit the Gambia), Céline Brochier‐Armanet(Aix-Marseille Université), Valentin Tilloy(Inserm), Florence Le Calvez‐Kelm(Centre international de recherche sur le cancer), Maimuna Mendy(Centre international de recherche sur le cancer), Janet Hall(Centre international de recherche sur le cancer), Ramou Njie(MRC Unit the Gambia), A. Dubois(Université Claude Bernard Lyon 1)
Cited by 28
Related Papers
Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy
|The Lancet Infectious Diseases|2017|822
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
|Gastroenterology|2009|693
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539